Rasha Aboelhassan: Which maintenance immunotherapy should we choose for stage IV urothelial cancer

Rasha Aboelhassan shared a post on LinkedIn:

“Which maintenance immunotherapy should we choose for stage IV urothelial cancer?

Should we apply:

• JAVELIN-100?
• CHECKMATE 901?

These are the challenging questions for every member in urogenital cancer MDT.

What are the main reasons for choose between different types of immunotherapy?

We discussed all data and sub-groups analysis of both clinical trials

Finally, the MDT members were harmonious and complemented each other, as if they were playing a beautiful symphony aimed at the patient’s benefit.

I was honored by invitation as a speaker in 7th Oncology conference by Menoufia University.

Discussion was challenging but interesting as always.”

Source: Rasha Aboelhassan/LinkedIn

More posts by Rasha Aboelhassan on oncodaily.com

Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.